Former FDA exec charged with securities fraud, along with two hedge fund managers
A shocking case of insider trading has rocked the drug development world and beyond. Earlier this month, a former Food and Drug Administration (FDA) official and two hedge fund managers were indicted for insider trading that made them unlawful profits of about $32 million. On June 15, the Securities and Exchange Commission (SEC) charged the men with using inside information to buy stocks from companies that were soon to have generic drugs approved, with the former FDA official gleaning tips from friends still working at the FDA. According to the U.S. attorney’s office in New York, the three men colluded from 2005 to 2011.
Bioclinica debuts new divisions to support patient engagement
In a strategy to address the industry-wide challenges of patient engagement in clinical trials, the specialty services provider Bioclinica has announced the creation of two separate divisions, a Research Network and Patient Recruitment-Retention, under the company’s Global Clinical Research business segment.
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.